
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Hldgs is supported by a durable commercial base in WAKIX, with 2026 net revenue guidance reaffirmed at $1.00 billion–$1.04 billion versus a $1.03 billion FactSet consensus, while 2Q26 momentum included +450 net patients and 8,950 average patients on treatment. Its outlook is further strengthened by a credible pipeline that spans BP-205, EPX-100, pitolisant GR and HD, and ZYN002, giving the company multiple shots at growth across rare neurological and broader CNS indications. The planned CEO transition appears orderly rather than disruptive, and the company’s emphasis on preserving WAKIX exclusivity, expanding access, and advancing key data readouts through 2027 supports a positive fundamental view.
Bears say
Harmony Biosciences Hldgs is exposed to meaningful concentration risk because Wakix remains the key growth engine, so any slowdown in new patient additions or fresh competition in the sodium oxybate market could materially pressure revenue momentum. Its pipeline offers only partial diversification, and the cited risks around unsuccessful clinical trials in PWS, DM1, DS/LGS, and Fragile X, plus the possibility of earlier-than-expected generic pitolisant competition, weaken confidence in future growth durability. Although a long 25 hr half life and clean safety profile may support dosing versus oveporexton, the balance of evidence still points to execution and competitive risks outweighing upside.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares